Format

Send to

Choose Destination
Clin Exp Allergy. 2012 Apr;42(4):513-22. doi: 10.1111/j.1365-2222.2011.03943.x.

12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg-Strauss syndrome.

Author information

1
Department of Medicine, Jagiellonian University Medical College, ul. Skawińska 8,Krakow, Poland. wszczeklik@gmail.com

Abstract

BACKGROUND:

Churg-Strauss syndrome (CSS) shares similarities with asthma and hypereosinophilic syndrome (HES). Eicosanoids--important inflammatory and signaling molecules--are present in exhaled breath condensate (EBC) and broncho-alveolar lavage fluid (BALF).

OBJECTIVES:

To assess eicosanoid profile both in EBC and BALF of CSS subjects searching for a pattern characteristic of this syndrome.

METHODS:

EBCs from 23 CSS patients, 30 asthmatics, 12 HES patients and 54 healthy controls (HC) were assessed quantitatively for 19 eicosanoids by a high-performance liquid chromatography - tandem mass spectrometry (HPLC-MS/MS). In addition, in 21 of 23 CSS subjects and in nine asthmatics, eicosanoids were determined in BALF.

RESULTS:

EBC from CSS patients showed markedly elevated levels of 12-HETE as compared with other studied groups. BALF was characterized by a significant elevation of 12-HETE and its metabolite 12-tetranor HETE in CSS as compared with asthma. Clinical activity of CSS correlated with 12-HETE and its metabolites levels in BALF, but not in EBC.

CONCLUSION AND CLINICAL RELEVANCE:

CSS is clearly distinguished from bronchial asthma, and HES by a marked increase in 12-HETE concentration in both EBC and BALF. This points to a possible new pathogenic mechanism in CSS and may help in future in establishing the diagnosis of CSS.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center